Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

European Commission Gives Green Light To Bayer HealthCare's Flexyess

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the European Commission has issued its go ahead for the approval of the company's subgroup Bayer HealthCare's new low-dose combined oral contraceptive Flexyess. Based on the European Commission's positive decision, the Health Authorities of the EU Member States will grant national approvals in the coming weeks.

Flexyess will be the first low-dose combined oral contraceptive approved in the EU member states for a flexible extended regimen, offering women the option of 'personal period planning', meaning they can choose both the number and timing of their periods according to their needs.

Dr. Flemming Ornskov, chief marketing officer at Bayer HealthCare's Pharmaceuticals division, said, "Once Flexyess is launched, women will have the convenience and flexibility to influence the timing of their periods according to their individual needs."

Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
With disappointing earnings news generating some selling pressure, stocks have moved mostly lower in early trading on Friday. The major averages have slid firmly into negative territory after ending the previous session nearly flat. After reporting an unexpected drop in new orders for U.S. manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than expected in the month of June. British economic growth remained high as expected in the second quarter as a robust expansion in the dominant service sector, and industry completely offset the slight weakness in the construction sector. With the second quarter expansion, GDP returned to its pre-crisis level. Gross domestic product grew 0.8 percent sequentially in the second quarter, the same rate as seen in the first quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.